ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer
Journal of the National Cancer Institute Dec 06, 2017
Pietrantonio F et al. -ALK, ROS1, and NTRK fusions occur in 0.2%-2.4% of colorectal cancers. Metastatic colorectal cancer (mCRC) patients with rearrangements who benefited from anti-ALK, ROS, and TrkA-B-C therapies. ALK, ROS1, and NTRK rearrangements comprise a subtype of mCRC with a poor prognosis.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
